Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
For breast cancer patients on chemo, the way colony-stimulating factor is delivered — clinic, on-body device, or self-injection — doesn't meaningfully change the risk of febrile neutropenia. A large SWOG trial found FN rates were low and statistically similar across all three methods. What actually raises the risk? High-intensity chemo regimens and poorer baseline performance status.
When it comes to preventing febrile neutropenia (FN) in breast cancer patients on chemotherapy, a new study says the how of delivering colony-stimulating factor (CSF) matters far less than previously assumed. Whether patients received their prophylactic CSF in-clinic, via an on-body device, or through self-injection, FN rates stayed low and statistically comparable across all three groups.
The findings come from a secondary analysis of the SWOG S1415CD trial, which enrolled 1,713 women with breast cancer receiving first-line chemotherapy. Researchers found that what did drive FN risk were clinical factors — specifically, high-risk chemotherapy regimens and worse performance status — not the delivery method or the specific CSF agent used.
By the Numbers:
Why it matters: These results give clinicians and patients more flexibility. Delivery method can now be chosen based on patient preference, insurance coverage, and logistical convenience — without worrying it will compromise protection against a serious, potentially life-threatening complication of chemotherapy.
